The company, which is collaborating with Myeloma Crowd, will use the newly-licensed minicircle DNA technology to develop therapies for multiple myeloma.
The partners aim to create a broad collection of high-quality genomic and clinical data from multiple myeloma patients to improve disease diagnosis, prognosis, and treatment.
The researchers' analysis of single circulating multiple myeloma tumor cells found that the results were similar to analysis of bone marrow biopsy samples.
The test is designed to replace gel electrophoresis assays currently used for measuring M-proteins, biomarkers for plasma cell diseases such as multiple myeloma.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
The partners said they will use genetic sequencing and a combination therapy to determine predictors of sustained minimal residual disease negativity.
The partners will perform genomic sequencing on multiple myeloma patients in order to generate data that can help guide personalized treatments.
In Nucleic Acids Research this week: competitive endogenous RNAs, transcriptomic and proteomic analysis of Plasmodium falciparum, and more.
The UPenn-led study proposal calls for editing three genes in autologous T cells with CRISPR and includes preliminary data for on- and off-target editing.
The company said sales of its MyPRS test for myeloma risk increased during the quarter, but full-year 2015 revenues fell because of increased R&D costs.
Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.
Some science companies will be taking part in next month's March for Science, Fortune reports.
In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.
Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.